

Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Information for the public

Published: 24 February 2021

www.nice.org.uk

Dapagliflozin (Forxiga) is available on the NHS as a possible treatment for symptomatic chronic heart failure with reduced ejection fraction in adults. This is only if it's used as an add-on to standard care. Standard care is:

- angiotensin-converting enzyme (ACE) inhibitors or angiotensin-2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
- sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.

Your doctor should get the advice of a heart failure specialist before discussing with you whether you want to start treatment with dapagliflozin. If you do start treatment you should be monitored by an appropriate healthcare professional.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Cardiomyopathy UK](#), 0800 018 1024
- [Pumping Marvellous Foundation](#), 01772 796542
- [South Asian Health Foundation](#), 07807 069719
- [British Heart Foundation](#), 0300 330 3311

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4061-5